Literature DB >> 11102404

A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia.

M B Avison1, C J von Heldreich, C S Higgins, P M Bennett, T R Walsh.   

Abstract

A constitutively expressed beta-lactamase gene from a clinical isolate of Stenotrophomonas maltophilia, J675Ia, has been cloned. Its DNA sequence is almost identical to that of bla(TEM2) (one nucleotide change) and the expressed enzyme is a Bush type 2a penicillinase with an amino acid sequence identical to that of TEM-2. The bla(TEM) gene was present within a novel Tn1/Tn3-type transposon in the genome of isolate J675Ia and the transposon was able to mobilize bla(TEM) on to the broad host-range conjugative plasmid, R388. When transferred to an Escherichia coli recipient, R388::Tn conferred high-level ampicillin resistance. This represents the first identification of a TEM beta-lactamase in S. maltophilia and the first evidence that this important clinical pathogen is able to act as a reservoir for mobile beta-lactamase genes in the hospital environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102404     DOI: 10.1093/jac/46.6.879

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene.

Authors:  Laurent Poirel; Jean-Winoc Decousser; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  YieJ (CbrC) mediates CreBC-dependent colicin E2 tolerance in Escherichia coli.

Authors:  S James L Cariss; Chrystala Constantinidou; Mala D Patel; Yuiko Takebayashi; Jon L Hobman; Charles W Penn; Matthew B Avison
Journal:  J Bacteriol       Date:  2010-04-23       Impact factor: 3.490

3.  Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

4.  Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

5.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

Review 6.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

7.  Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in Stenotrophomonas maltophilia.

Authors:  Punyawee Dulyayangkul; Karina Calvopiña; Kate J Heesom; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

8.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Stenotrophomonas maltophilia encodes a type II protein secretion system that promotes detrimental effects on lung epithelial cells.

Authors:  Sara M Karaba; Richard C White; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

10.  Diffusible signal factor-dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia.

Authors:  Yvonne Fouhy; Karl Scanlon; Katherine Schouest; Charles Spillane; Lisa Crossman; Matthew B Avison; Robert P Ryan; J Maxwell Dow
Journal:  J Bacteriol       Date:  2007-04-27       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.